- Home
- PYPD vs KZIA Comparison
PYPD vs KZIA Comparison
Compare PYPD & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- KZIA
- Stock Information
- Founded
- PYPD 2008
- KZIA 1994
- Country
- PYPD Israel
- KZIA Australia
- Employees
- PYPD N/A
- KZIA N/A
- Industry
- PYPD Medical/Dental Instruments
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- KZIA Health Care
- Exchange
- PYPD Nasdaq
- KZIA Nasdaq
- Market Cap
- PYPD 16.5M
- KZIA 18.7M
- IPO Year
- PYPD 2020
- KZIA 1999
- Fundamental
- Price
- PYPD $2.93
- KZIA $3.18
- Analyst Decision
- PYPD Strong Buy
- KZIA Strong Buy
- Analyst Count
- PYPD 2
- KZIA 1
- Target Price
- PYPD $12.00
- KZIA $20.00
- AVG Volume (30 Days)
- PYPD 28.7K
- KZIA 77.0K
- Earning Date
- PYPD 02-12-2025
- KZIA 12-27-2024
- Dividend Yield
- PYPD N/A
- KZIA N/A
- EPS Growth
- PYPD N/A
- KZIA N/A
- EPS
- PYPD N/A
- KZIA N/A
- Revenue
- PYPD N/A
- KZIA $1,655,324.00
- Revenue This Year
- PYPD N/A
- KZIA $806.89
- Revenue Next Year
- PYPD N/A
- KZIA N/A
- P/E Ratio
- PYPD N/A
- KZIA N/A
- Revenue Growth
- PYPD N/A
- KZIA 248000.00
- 52 Week Low
- PYPD $2.37
- KZIA $1.90
- 52 Week High
- PYPD $9.20
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- PYPD 33.37
- KZIA 29.92
- Support Level
- PYPD $2.37
- KZIA $3.00
- Resistance Level
- PYPD $3.13
- KZIA $4.20
- Average True Range (ATR)
- PYPD 0.24
- KZIA 0.56
- MACD
- PYPD -0.06
- KZIA -0.15
- Stochastic Oscillator
- PYPD 19.30
- KZIA 5.82
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.